821 Magnetic resonance image-guided prostate biopsy versus transperineal template prostate biopsy in the diagnosis of clinically significant prostate cancer

2012 ◽  
Vol 11 (1) ◽  
pp. e821-e821a
Author(s):  
V. Kasivisvanathan ◽  
R. Dufour ◽  
C.M. Moore ◽  
H.U. Ahmed ◽  
A. Freeman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Prostate Biopsy ◽  
Magnetic Resonance Image ◽  
Image Guided ◽  
Clinically Significant

2049 MAGNETIC RESONANCE IMAGE-GUIDED PROSTATE BIOPSY VERSUS TRANSPERINEAL TEMPLATE PROSTATE BIOPSY IN THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Veeru Kasivisvanathan ◽  
Robert Dufour ◽  
Caroline Moore ◽  
Hashim Ahmed ◽  
Alex Freeman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Prostate Biopsy ◽  
Magnetic Resonance Image ◽  
Image Guided ◽  
Clinically Significant

Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer

2013 ◽  
Vol 189 (3) ◽  
pp. 860-866 ◽  
Author(s):  
Veeru Kasivisvanathan ◽  
Robert Dufour ◽  
Caroline M. Moore ◽  
Hashim U. Ahmed ◽  
Mohamed Abd-Alazeez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Prostate Biopsy ◽  
Magnetic Resonance Image ◽  
Clinically Significant

One-year experience of government-funded magnetic resonance imaging prior to prostate biopsy: A case for omitting biopsy in men with a negative magnetic resonance imaging

2021 ◽  
pp. 205141582110043
Author(s):  
Hanna J El-Khoury ◽  
Niranjan J Sathianathen ◽  
Yuxin Jiao ◽  
Reza Farzan ◽  
Dennis Gyomber ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Prostate Biopsy ◽  
Multivariable Analysis ◽  
Transrectal Ultrasound ◽  
Resonance Imaging ◽  
Retrospective Case ◽  
Level Of Evidence ◽  
Clinically Significant

Objectives: This study aimed to characterise the accuracy of multiparametric magnetic resonance imaging (mpMRI) as an adjunct to prostate biopsy, and to assess the effect of the new Australian Medicare rebate on practice at a metropolitan public hospital. Patients and methods: We identified patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsy at a single institution over a two-year period. Patients were placed into two groups, depending upon whether their consent was obtained before or after the introduction of the Australian Medicare rebate for mpMRI. We extracted data on mpMRI results and TRUS-guided biopsy histopathology. Descriptive statistics were used to demonstrate baseline patient characteristics as well as MRI and histopathology results. Results: A total of 252 patients were included for analysis, of whom 128 underwent biopsy following the introduction of the Medicare rebate for mpMRI. There was a significant association between Prostate Imaging Reporting and Data System v2 (PI-RADS) classification and the diagnosis of clinically significant prostate cancer ( p<0.01). Only one man with PI-RADS ⩽2 was found to have clinically significant prostate cancer. Four men with a PI-RADS 3 lesion were found to have clinically significant cancer. A PI-RADS 4 or 5 lesion was significantly associated with the diagnosis of clinically significant cancer on multivariable analysis. Conclusion: mpMRI is an important adjunct to biopsy in the diagnosis of clinically significant prostate cancer. Our findings support the safety of omitting/delaying prostate biopsy in men with negative mpMRI. Level of evidence: Level 3 retrospective case-control study.

Magnetic resonance image‐guided focal laser ablation in clinically localized prostate cancer: safety and efficacy

2019 ◽  
Vol 89 (12) ◽  
pp. 1610-1614 ◽  
Author(s):  
Yasser Al‐Hakeem ◽  
Orit Raz ◽  
Zita Gacs ◽  
Fiona Maclean ◽  
Celi Varol
Keyword(s):  
Prostate Cancer ◽  
Laser Ablation ◽  
Magnetic Resonance ◽  
Magnetic Resonance Image ◽  
Localized Prostate Cancer ◽  
Safety And Efficacy ◽  
Image Guided

TRANSPERINEAL MAGNETIC RESONANCE IMAGE GUIDED PROSTATE BIOPSY

2000 ◽  
Vol 164 (2) ◽  
pp. 385-387 ◽  
Author(s):  
A.V. D’AMICO ◽  
C.M. TEMPANY ◽  
R. CORMACK ◽  
N. HATA ◽  
M. JINZAKI ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Prostate Biopsy ◽  
Magnetic Resonance Image ◽  
Image Guided

scholarly journals MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy

2018 ◽  
Vol 2018 ◽  
pp. 1-10
Author(s):  
Cong Huang ◽  
Gang Song ◽  
He Wang ◽  
Guangjie Ji ◽  
Jie Li ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Prostate Biopsy ◽  
Curve Analysis ◽  
Resonance Imaging ◽  
Decision Curve Analysis ◽  
Multiparametric Magnetic Resonance Imaging ◽  
Clinically Significant ◽  
Systematic Prostate Biopsy

Objective. To develop and internally validate nomograms based on multiparametric magnetic resonance imaging (mpMRI) to predict prostate cancer (PCa) and clinically significant prostate cancer (csPCa) in patients with a previous negative prostate biopsy. Materials and Methods. The clinicopathological parameters of 231 patients who underwent a repeat systematic prostate biopsy and mpMRI were reviewed. Based on Prostate Imaging and Reporting Data System, the mpMRI results were assigned into three groups: Groups “negative,” “suspicious,” and “positive.” Two clinical nomograms for predicting the probabilities of PCa and csPCa were constructed. The performances of nomograms were assessed using area under the receiver operating characteristic curves (AUCs), calibrations, and decision curve analysis. Results. The median PSA was 15.03 ng/ml and abnormal DRE was presented in 14.3% of patients in the entire cohort. PCa was detected in 75 patients (32.5%), and 59 (25.5%) were diagnosed with csPCa. In multivariate analysis, age, prostate-specific antigen (PSA), prostate volume (PV), digital rectal examination (DRE), and mpMRI finding were significantly independent predictors for PCa and csPCa (all p < 0.01). Of those patients diagnosed with PCa or csPCa, 20/75 (26.7%) and 18/59 (30.5%) had abnormal DRE finding, respectively. Two mpMRI-based nomograms with super predictive accuracy were constructed (AUCs = 0.878 and 0.927, p < 0.001), and both exhibited excellent calibration. Decision curve analysis also demonstrated a high net benefit across a wide range of probability thresholds. Conclusion. mpMRI combined with age, PSA, PV, and DRE can help predict the probability of PCa and csPCa in patients who underwent a repeat systematic prostate biopsy after a previous negative biopsy. The two nomograms may aid the decision-making process in men with prior benign histology before the performance of repeat prostate biopsy.

Sign in / Sign up

Export Citation Format

Share Document